Sirolimus-eluting stents for coronary revascularization

Cardiology Review

Volumn 20, Issue 5, 2003, Pages 36-39

  Morice, Marie Claude ^a  

^a INSTITUT CARDIOVASCULAIRE PARIS SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; RAPAMYCIN;

ADULT; AGED; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTICLE; CENTRAL AMERICA; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; CORONARY STENT; DEATH; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ELUTING STENT; EUROPE; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INTRAVASCULAR ULTRASOUND; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; RETREATMENT; SOUTH AMERICA; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0037607234     PISSN: 10926607     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Sigwart U, Puel J, Mirkovitch V, et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med. 1987;316 (12):701-706.
2. Roubin GS, Cannon AD, Agrawal SK, et al. Intracoronary stenting for acute and threatened closure complicating percutaneous transluminal coronary angioplasty. Circulation. 1992;85(3):916-927.
3. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med. 1994;331(8):489-495.
4. Dussaillant GR, Mintz GS, Pichard AD, et al. Small stent size and intimal hyperplasia contribute to restenosis: a volumetric intravascular ultrasound analysis. J Am Coll Cardiol. 1995;26(3): 720-724.
5. Hoffmann R, Mintz GS, Dussaillant GR, et al. Patterns and mechanisms of in-stent restenosis: a serial intravascular ultrasound study. Circulation. 1996; 94(6):1247-1254.
6. Serruys PW, Unger F, Sousa E, et al. Comparison of coronary artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med. 2001;344(15):1117-1124.
7. Marx SO, Marks AR. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation. 2001;104(8):852-855.
8. Burke SE, Lubbers NL, Chen YW, et al. Neointimal formation after balloon induced vascular injury in Yucatan mini pigs is reduced by oral rapamycin. J Cardiovasc Pharmacol. 1999;33 (6):829-835.
9. Serruys PW, van Hout B, Bonnier H, et al. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet. 1998;352(9129): 673-681.
10. de Feyter PJ, Vos J, Rensing BJ. Antirestenosis trials. Curr Interv Cardiol Rep. 2000;2(4):326-331.
11. Kastrati A, Schomig A, Dirschinger J, et al. Increased risk of restenosis after placement of gold-coated stents: results of a randomized trial comparing gold-coated with uncoated steel stents in patients with coronary artery disease. Circulation. 2000;101(21)-2478-2483.
12. Mehran R, Dangas G, Mintz GS, et al. Treatment of in-stent restenosis with excimer laser coronary angioplasty versus rotational atherectomy: comparative mechanisms and results. Circulation. 2000;101(21):2484-2489.
13. Teirstein PS, Massullo V, Jani S, et al. Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med. 1997;336(24):1697-1703.